Xeris Biopharma’s August 6, 2026 update showed second-quarter revenue rising to US$92.1 million while net loss widened to US$31.1 million, and the company tightened its full-year 2026 total revenue guidance to US$385 million–US$390 million. Alongside record quarterly revenue, Xeris highlighted strong Recorlev momentum, full retirement of its convertible notes, and progress toward a Phase III start for XP-8121, reshaping its operational profile. We’ll now examine how this tighter 2026 revenue...

Xeris Biopharma Holdings (XERS) is back in focus after reporting record second quarter revenue of $92.1 million and tightening its 2026 revenue outlook to a range of $385 million to $390 million. See our latest analysis for Xeris Biopharma Holdings. The latest record quarter and tighter 2026 revenue outlook have arrived after a strong run in Xeris Biopharma Holdings' stock, with a 33.49% 90 day share price return and a 292.92% three year total shareholder return, although the 1 day share...

Recorlev revenue surged 81% year-over-year, driving tightened full-year guidance to $385M–$390M.

Xeris Biopharma (NASDAQ:XERS) reported second-quarter total revenue of $92.1 million, up 29% from a year earlier, as net product revenue increased 34% to $91 million. The company raised the low end of its full-year 2026 revenue outlook, now forecasting total revenue of $385 million to $390 million.

Xeris Biopharma Holdings Inc (XERS) posts a 29% revenue surge to $92.1 million, driven by RECORLEV's 81% growth, and lifts full-year 2026 outlook.

The headline numbers for Xeris Biopharma (XERS) give insight into how the company performed in the quarter ended June 2026, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.

Zevra Therapeutics (ZVRA) delivered earnings and revenue surprises of +212.50% and +22.76%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?